AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11510868 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Fluoxetine-HCI (Prozac, Ely Lilly Belgium)
Number of subjects: 8
Study 11510868 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 8
Study 9760816 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical removal of a parathyroid adenoma
Number of subjects: 39
Study 9760816 — intervention group
Group type: COMPARATOR
Intervention: Primary hyperparathyroidism
Number of subjects: 39
Study 9760816 — intervention group
Group type: COMPARATOR
Intervention: Secondary hyperparathyroidism
Number of subjects: 39
Study 9760816 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 39
Study 7802236 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium followed by spontaneous recovery (n = 10)
Number of subjects: 50
Study 7802236 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 50 micrograms.kg‐1 at T1 of 10% (n = 10)
Number of subjects: 50
Study 7802236 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg.kg‐1 at T1 of 10% (n = 10)
Number of subjects: 50
Study 7802236 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 50 micrograms.kg‐1 at T1 of 25% (n = 10)
Number of subjects: 50
Study 7802236 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg.kg‐1 at T1 of 25% (n = 10)
Number of subjects: 50
Study 7802236 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine and Edrophonium groups
Number of subjects: 50
Study 7802236 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium at T1 of 10% (n = 10)
Number of subjects: 50
Study 7802236 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine at T1 of 25% (n = 10)
Number of subjects: 50
Study 3431377 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose polymer
Number of subjects: 13
Study 3431377 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% sucrose/glucose
Number of subjects: 13
Study 3431377 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% glucose polymer/fructose
Number of subjects: 13
Study 3431377 — intervention group
Group type: COMPARATOR
Intervention: water placebo
Number of subjects: 13
Study 28881471 — intervention group
Group type: EXPERIMENTAL
Intervention: Education sessions coordinated through partner hospitals
Number of subjects: 351
Study 28881471 — intervention group
Group type: COMPARATOR
Intervention: Letters to women on state and hospital registries
Number of subjects: 351
Study 28881471 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study sample
Number of subjects: 351
Study 26690008 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 141
Study 26690008 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropins only (Control)
Number of subjects: 141
Study 25567713 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (or clindamycin)
Number of subjects: 96
Study 25567713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 23623450 — intervention group
Group type: EXPERIMENTAL
Intervention: rs5992403 AA-genotype carriers
Number of subjects: 299
Study 23623450 — intervention group
Group type: COMPARATOR
Intervention: Control group (363 controls)
Number of subjects: 299
Study 22035462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ossein-hydroxyapatite complex (OHC)
Number of subjects: 120
Study 22035462 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 120
Study 18252814 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperalimentation (intervention group)
Number of subjects: 142
Study 18252814 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral and enteral nutrition (control group)
Number of subjects: 142
Study 16803724 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanomyography (MMG) biofeedback
Number of subjects: 0
Study 16803724 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyography (EMG) biofeedback
Number of subjects: 0
Study 16803724 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio and visual biofeedback
Number of subjects: 0
Study 12604409 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched parenteral nutrition (20 g) from day +1 after aPBSCT in study 1
Number of subjects: 48
Study 12604409 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched parenteral nutrition (13.46 g) from day +1 after aPBSCT in study 2
Number of subjects: 48
Study 12604409 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched parenteral nutrition
Number of subjects: 48
Study 12604409 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TPN lacking glutamine) in study 1
Number of subjects: 48
Study 12604409 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TPN lacking glutamine) in study 2
Number of subjects: 48
Study 10694002 — intervention group
Group type: EXPERIMENTAL
Intervention: MenD (bivalent meningococcal A + C diphtheria‐toxoid‐conjugated vaccine)
Number of subjects: 0
Study 10694002 — intervention group
Group type: EXPERIMENTAL
Intervention: MenD (4 microg or 16 microg)
Number of subjects: 0
Study 10694002 — intervention group
Group type: COMPARATOR
Intervention: MenPS (meningococcal A + C polysaccharide vaccine)
Number of subjects: 0
Study 10694002 — intervention group
Group type: COMPARATOR
Intervention: H. influenzae type b‐tetanus toxoid‐conjugated vaccine
Number of subjects: 0
Study 10694002 — intervention group
Group type: COMPARATOR
Intervention: MenD vs MenPS
Number of subjects: 0
Study 9169958 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-dosing (PD) of doxepin (250 mg every 6 days)
Number of subjects: 19
Study 9169958 — intervention group
Group type: COMPARATOR
Intervention: Conventional (CONV) application of doxepin (increasing dosages until day 7, then 250 mg on other days)
Number of subjects: 19
Study 8227809 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression technique
Number of subjects: 5
Study 8227809 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 5
Study 6407050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (300-600 mg/day)
Number of subjects: 75
Study 6407050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 31520284 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment over 6 months
Number of subjects: 150
Study 31520284 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (control group)
Number of subjects: 150
Study 29666683 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-facilitated training
Number of subjects: 120
Study 29666683 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based training
Number of subjects: 120
Study 29666683 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined peer-and-video training
Number of subjects: 120
Study 29666683 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 120
Study 26996043 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosehip Oil (ARM, Repavar®) applied twice daily from the beginning of treatment
Number of subjects: 62
Study 26996043 — intervention group
Group type: COMPARATOR
Intervention: Control group with different skin treatments
Number of subjects: 62
Study 25189490 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibitor perindopril
Number of subjects: 27492
Study 25189490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27492
Study 22225620 — intervention group
Group type: EXPERIMENTAL
Intervention: Pateclizumab 3.0 mg/kg SC (MAD group)
Number of subjects: 50
Study 22225620 — intervention group
Group type: EXPERIMENTAL
Intervention: Pateclizumab (all doses)
Number of subjects: 50
Study 22225620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19149503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (1g)‐Tobramycin (120mg)
Number of subjects: 240
Study 19149503 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (1g) alone
Number of subjects: 240
Study 17394629 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervisors contact their employee six weeks after delivery using a structured interview and offer early support of the occupational physician if needed.
Number of subjects: 0
Study 17394629 — intervention group
Group type: COMPARATOR
Intervention: No structural contact with employees during maternity leave.
Number of subjects: 0
Study 16505415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5CMV‐p53 monotherapy (1 x 10(9) to 1 x 10(11) plaque‐forming units)
Number of subjects: 15
Study 16505415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5CMV‐p53 in combination with intravenous cisplatin (80 mg/m2)
Number of subjects: 15
Study 16505415 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall efficacy assessment
Number of subjects: 15
Study 15136392 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic discontinuation policy
Number of subjects: 290
Study 15136392 — intervention group
Group type: COMPARATOR
Intervention: Conventional antibiotic management
Number of subjects: 290
Study 10883661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-containing regimen
Number of subjects: 4054
Study 8646440 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient multidisciplinary treatment for 11 days followed by standard out-patient care (n = 39)
Number of subjects: 80
Study 8646440 — intervention group
Group type: COMPARATOR
Intervention: Standard out-patient care only (n = 41)
Number of subjects: 80
Study 1814964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 41
Study 1814964 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Number of subjects: 41
Study 1814964 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 41
Study 6848334 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of nifedipine
Number of subjects: 10
Study 6848334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31630098 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications (LSM) intervention
Number of subjects: 42
Study 28302532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Tear Neurostimulator (ITN)
Number of subjects: 15
Study 28302532 — intervention group
Group type: COMPARATOR
Intervention: Extranasal sham application
Number of subjects: 15
Study 26687550 — intervention group
Group type: EXPERIMENTAL
Intervention: Current anti-HTN management
Number of subjects: 45
Study 26687550 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen failure group
Number of subjects: 45
Study 26687550 — intervention group
Group type: EXPERIMENTAL
Intervention: Average number of medications
Number of subjects: 45
Study 26687550 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization for cardiovascular and HTN urgency/emergency
Number of subjects: 45
Study 23451764 — intervention group
Group type: EXPERIMENTAL
Intervention: TU-100 2.5 g t.d.s.
Number of subjects: 45
Study 23451764 — intervention group
Group type: EXPERIMENTAL
Intervention: TU-100 5 g t.d.s.
Number of subjects: 45
Study 23451764 — intervention group
Group type: COMPARATOR
Intervention: Placebo t.d.s.
Number of subjects: 45
Study 21453356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive performance in adults with new-onset epilepsy after 12 months
Number of subjects: 147
Study 21453356 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 147
Study 21453356 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate treatment
Number of subjects: 147
Study 21453356 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized seizures
Number of subjects: 147
Study 21453356 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate 12-month seizure remission
Number of subjects: 147
Study 18037667 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil TCI
Number of subjects: 24
Study 18037667 — intervention group
Group type: COMPARATOR
Intervention: Propofol TCI
Number of subjects: 24
Study 16611703 — intervention group
Group type: EXPERIMENTAL
Intervention: SIPA (System of Integrated Care for Older Persons)
Number of subjects: 0
Study 16611703 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 12558620 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical paromomycin
Number of subjects: 96
Study 12558620 — intervention group
Group type: COMPARATOR
Intervention: Intralesional meglumine antimoniate
Number of subjects: 96
Study 10969274 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to the apex
Number of subjects: 200
Study 10969274 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpating the apex beat
Number of subjects: 200
Study 10969274 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpating the carotid pulse
Number of subjects: 200
Study 10969274 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpating the brachial pulse
Number of subjects: 200
Study 8840744 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive pharmacy services including monthly blood pressure and heart rate assessments, counseling on lifestyle modifications and drug therapy
Number of subjects: 53
Study 8840744 — intervention group
Group type: COMPARATOR
Intervention: Minimal counseling and initial/final blood pressure measurements
Number of subjects: 53
Study 1378641 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cycles of induction chemotherapy with Bleomycin, Methotrexate and Hydroxyurea before definitive external radiotherapy (60 Gy)
Number of subjects: 49
Study 1378641 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cycles of chemotherapy administered between the 20‐ and the 40‐Gy doses
Number of subjects: 49
Study 1378641 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (60 Gy) alone
Number of subjects: 49
Study 6387192 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy combined with temporary arteriovenous fistula and anticoagulation
Number of subjects: 63
Study 6387192 — intervention group
Group type: COMPARATOR
Intervention: Conventional anticoagulation
Number of subjects: 63
Study 31248435 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping with Uncertainty in Everyday Situations (CUES)
Number of subjects: 60
Study 31248435 — intervention group
Group type: COMPARATOR
Intervention: Enhanced services as usual (brief psychoeducation, emotional literacy, and relaxation programme)
Number of subjects: 60
Study 29047128 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg fentanyl + 10 ml bupivacaine 0.08% (F20 group)
Number of subjects: 105
Study 29047128 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg fentanyl + 10 ml bupivacaine 0.08% (F50 group)
Number of subjects: 105
Study 29047128 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg fentanyl + 10 ml bupivacaine 0.08% (F100 group)
Number of subjects: 105
Study 29047128 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg fentanyl (F20 group)
Number of subjects: 105
Study 29047128 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg fentanyl (F50 group)
Number of subjects: 105
Study 29047128 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg fentanyl (F100 group)
Number of subjects: 105
Study 27282865 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide (0.6 mg for 7 days, 1.2 mg for 7 days, 1.8 mg for 3 days)
Number of subjects: 20
Study 27282865 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 25155593 — intervention group
Group type: EXPERIMENTAL
Intervention: AVI-6002 (0.005, 0.05, 0.5, 1.5, 3, and 4.5 mg/kg per component)
Number of subjects: 30
Study 25155593 — intervention group
Group type: EXPERIMENTAL
Intervention: AVI-6003 (0.005, 0.05, 0.5, 1.5, 3, and 4.5 mg/kg per component)
Number of subjects: 30
Study 25155593 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4:1 ratio with active study drug)
Number of subjects: 30
Study 23271778 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 695
Study 23271778 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 695
Study 23271778 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy and hormonal treatments
Number of subjects: 695
Study 23271778 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural aging
Number of subjects: 695
Study 19161950 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and TENS (A&T)
Number of subjects: 32
Study 17122090 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (100 mg)
Number of subjects: 8
Study 17122090 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 8
Study 15896580 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.2 mg/kg
Number of subjects: 60
Study 15896580 — intervention group
Group type: COMPARATOR
Intervention: No rocuronium (saline control)
Number of subjects: 60
Study 15896580 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 60
Study 11518827 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (35% nonprotein energy as carbohydrate, 130 kcal x kg(‐1) x d(‐1))
Number of subjects: 5
Study 11518827 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (65% nonprotein energy as carbohydrate, 130 kcal x kg(‐1) x d(‐1))
Number of subjects: 5
Study 11518827 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (35% nonprotein energy as carbohydrate, 155 kcal x kg(‐1) x d(‐1))
Number of subjects: 5
Study 11518827 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (65% nonprotein energy as carbohydrate, 155 kcal x kg(‐1) x d(‐1))
Number of subjects: 5
Study 11518827 — intervention group
Group type: COMPARATOR
Intervention: Control group (50% nonprotein energy as carbohydrate, 130 kcal x kg(‐1) x d(‐1))
Number of subjects: 5
Study 9627910 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamins (beta-carotene, 6 mg; vitamin C, 120 mg; and vitamin E, 30 mg) and trace elements (zinc, 20 mg; and selenium, 100 micrograms)
Number of subjects: 401
Study 9627910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 9627910 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamins and trace elements
Number of subjects: 401
Study 7877824 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophagocardiomyotomy with Dor gastroplasty
Number of subjects: 13
Study 2896635 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (n = 9)
Number of subjects: 24
Study 2896635 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (n = 7)
Number of subjects: 24
Study 2896635 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 24
Study 2896635 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade (Session 2)
Number of subjects: 24
Study 2896635 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (Session 3)
Number of subjects: 24
Study 2896635 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of active medication (Session 4)
Number of subjects: 24
Study 2896635 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Sessions 1 to 2)
Number of subjects: 24
Study 30410133 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics (RETN C-420G SNP)
Number of subjects: 789
Study 30410133 — intervention group
Group type: COMPARATOR
Intervention: Controls (healthy individuals)
Number of subjects: 789
Study 28545518 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks (Q2W)
Number of subjects: 413
Study 28545518 — intervention group
Group type: COMPARATOR
Intervention: Lipid-lowering usual care (including maximally tolerated statin therapy, with options to add ezetimibe, fenofibrate, omega-3 fatty acids, or nicotinic acid)
Number of subjects: 413
Study 28545518 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W (for those with non-HDL-C ≥100 mg/dl at week 8)
Number of subjects: 413
Study 28545518 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate (in secondary analysis)
Number of subjects: 413
Study 26204418 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with bupivacaine
Number of subjects: 49
Study 26204418 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 49
Study 23948514 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy
Number of subjects: 488
Study 23948514 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving CRP level below the median
Number of subjects: 488
Study 23948514 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving LDL-C below the median
Number of subjects: 488
Study 21126920 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGB with ≥ 2 imbrication sutures
Number of subjects: 100
Study 21126920 — intervention group
Group type: COMPARATOR
Intervention: SAGB without imbrication sutures
Number of subjects: 100
Study 18198262 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 23
Study 18198262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17165363 — intervention group
Group type: EXPERIMENTAL
Intervention: g-hydroxybutyrate (GHB, 50 mg/kg of body weight t.i.d)
Number of subjects: 86
Study 17165363 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone (NTX, 50 mg/day)
Number of subjects: 86
Study 17165363 — intervention group
Group type: EXPERIMENTAL
Intervention: disulfiram (DSF, 200 mg/day)
Number of subjects: 86
Study 14581707 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate A
Number of subjects: 19
Study 14581707 — intervention group
Group type: COMPARATOR
Intervention: Alginate B
Number of subjects: 19
Study 10768307 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) as adjunctive therapy; mean dosage 9 mg/kg/day
Number of subjects: 83
Study 10768307 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 83
Study 9324170 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid meal (vanilla milk drink)
Number of subjects: 8
Study 9324170 — intervention group
Group type: COMPARATOR
Intervention: Solid meal (pasta with vegetables)
Number of subjects: 8
Study 8320247 — intervention group
Group type: EXPERIMENTAL
Intervention: ATGAM
Number of subjects: 79
Study 8320247 — intervention group
Group type: COMPARATOR
Intervention: MALG
Number of subjects: 79
Study 8320247 — intervention group
Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 79
Study 3802724 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mumol of lithium carbonate given orally in single doses
Number of subjects: 5